ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech entity specializing in blockchain-driven payment and trading solutions for global merchants and financial institutions, has expressed its enthusiasm following the enactment of the GENIUS Act. This pivotal U.S. legislation creates a framework for the regulation and oversight of stablecoin issuance. Peter Tassiopoulos, the CEO of ALT5 Sigma, remarked, “This legislation signifies a major shift. With a definitive legal structure in place, U.S. businesses can now innovate with assurance and harness the transformative potential of blockchain technology.”
From its inception, ALT5’s infrastructure has been crafted to facilitate the responsible and compliant adoption of digital assets on a large scale, aligning with the principles now solidified in law. The company views this legislation as a vital advancement that will equalize opportunities for regulated participants while safeguarding the industry from fraudulent activities and systemic risks.
In 2024, stablecoins facilitated an astonishing $27.6 trillion USD in on-chain transactions, which outpaced the annual transaction volumes of both Visa and Mastercard combined. Their significance in cross-border payments, remittances, and on-platform settlements is increasingly recognized, especially among fintech companies and institutional players aiming for enhanced efficiency and transparency.
To date, ALT5 has handled over $5 billion USD in cryptocurrency transactions, serving more than 1,000 businesses globally. The firm continues to observe a surge in demand for infrastructure related to stablecoins as enterprises increasingly seek to incorporate blockchain-based payment systems into their operations. ALT5 is supportive of prudent regulations and appreciates the ongoing initiatives by U.S. lawmakers aimed at establishing more structure and transparency within the digital asset landscape. As adoption rates rise, this regulatory clarity is anticipated to facilitate ALT5’s sustained growth in a rapidly evolving global market.
About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech firm that offers advanced blockchain technologies designed for the tokenization, trading, clearing, settlement, payment, and safekeeping of digital assets. Established in 2018, ALT5 Sigma, Inc., a fully-owned subsidiary, is pioneering the transition to a new global financial framework through its comprehensive suite of blockchain infrastructure solutions. The company provides two primary platforms: “ALT5 Pay” and “ALT5 Prime.” Since its inception, it has processed over $5 billion USD in cryptocurrency transactions.
ALT5 Pay is an award-winning payment gateway that enables approved global merchants to accept and facilitate cryptocurrency transactions. Merchants can choose to convert transactions into fiat currencies automatically or receive payments in digital assets directly. Meanwhile, ALT5 Prime operates as an electronic over-the-counter trading platform, allowing registered clients to buy and sell digital assets. Customers can engage in transactions using fiat for purchasing and can also convert their digital assets back to fiat currency. ALT5 Prime can be accessed via a mobile application called “ALT5 Pro,” available for download on both the Apple App Store and Google Play, as well as through ALT5 Prime’s FIX API and Broadridge Financial Solutions’ NYFIX gateway for authorized clients.
The company is also working on separating its biotech business, which will proceed under the name “Alyea Therapeutics Corporation.” This division is focused on developing medications with non-addictive pain relief properties aimed at treating chronic or severe pain conditions. One of their patented products, a low-dose naltrexone formulation known as JAN123, is initially being developed to address Complex Regional Pain Syndrome (CRPS), a condition characterized by severe, persistent pain typically affecting limbs. The FDA has granted JAN123 Orphan Drug Designation for the treatment of CRPS.
Forward-Looking Statements
This announcement contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements may pertain to ALT5’s potential profitability and growth, including but not limited to risks associated with international currency fluctuations, third-party credit risks, liability issues stemming from ALT5’s services, and technological challenges affecting future expansion. The release may also reference risks related to the development and anticipated outcomes of JAN 101 and JAN 123, the timeline for clinical trials, the FDA’s approval process for JAN 123, and other projections that may use terms like “continue,” “expect,” “intend,” “will,” “hope,” “should,” “would,” “may,” “potential,” and similar phrases. These statements represent the Company’s current perspectives on future events and carry inherent risks and uncertainties based on various estimates and assumptions that, while deemed reasonable, are subject to significant unpredictability.
Numerous factors could result in actual outcomes diverging significantly from those anticipated in this announcement, including those outlined in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). If any of these risks or uncertainties materialize, or if the assumptions laid out in the “Risk Factors” sections of the Company’s SEC filings prove to be incorrect, the actual results may differ considerably from those described. These forward-looking statements are made as of the date of this announcement, and the Company does not intend to update them unless legally required. The accuracy of such statements cannot be guaranteed, and as such, future events may unfold differently than currently expected. Investors should be cautious and not overly rely on forward-looking statements due to their inherent uncertainties.
